This house believes that the UK healthcare system may be failing as many as 50% of patients with hyperlipidaemia by not reducing their cholesterol to effective levels: A debate

British Journal of Cardiology

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Weston, Clive ^a   Capps, Nigel ^b   Findley, Stewart ^c   Foxton, Julie ^d   Hobbs, Richard ^e   McCormack, Terry ^d   McMorran, Jim ^f   Pittard, John ^d   Procter King, Jan ^f  

^a SINGLETON HOSPITAL   (United Kingdom)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

^c Durham Dales PCT   (United Kingdom)

^d HEART ^*

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f CHD and Diabetes   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID; OMEGA 3 FATTY ACID; RESIN; SIMVASTATIN;

ARTICLE; CARDIOLOGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; GOVERNMENT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEPATITIS; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MEDICAL EXPERT; MYALGIA; NURSE; OPTIMAL DRUG DOSE; PATIENT CARE; RISK REDUCTION; UNITED KINGDOM;

EID: 21244439123     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. de Lusignan S, Dzregah B, Hague N et al. Cholesterol management in patients with IHD: an audit-based appraisal of progress towards clinical targets in primary care. Br J Cardiol 2003; 10:223-8.
2. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
3. Brady AJB, Norrie J, Ford I. Failure to achieve cholesterol targets with statins in UK general practice - the Performance for Life study. Abstract presented at Primary Care Cardiovascular Society, 3-4 October 2003, Dublin.
4. Department of Health. National Service Framework for Coronary Heart Disease. London:DoH, 2000.
5. British Heart Foundation. Coronary Heart Disease Statistics: Factsheet. 2004. http://www.bhf.org.uk/professionals/index /asp?secID=15&secondlevel=519 Date accessed 10.01.05.
6. British Heart Foundation. What part does cholesterol play in coronary heart disease? Heart Health. http://www.bhf.org.uk/hearthealth/index.asp?secID=1&secondlevel= 78&thirdlevel=166&artID=443 Date accessed 10.01.05.
7. Department of Health. The New GMS Contract: Investing in General Practice. Annex A. London:DoH, 2003. p56-71.
8. Evans PH, Luthra M, Pike C et al. NSF lipid targets in patients with CHD: are they achievable in a real-life primary care setting? Br J Cardiol 2003;10: 71-4.
9. Shah PK. Emerging non-statin LDL-lowering therapies for dyslipidaemia and atherosclerosis. Rev Cardiovasc Med 2003; 4:136-41.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7-22.
11. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341(7): 498-511.
12. Department of Health. Prescription Cost Analyses. 2003. http://www.publications.doh.gov.uk/stats/pca2003.htm Date accessed 12.11.04.
13. Feldman T, Koren M, Insull W et al. Treatment of high-risk patients with ezetimibe plus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004; 93:1481-6.
14. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. J Hum Hypertens 2004;18:139-85.
15. Hobbs R, Pittard J, Weston C et al. Action on Cholesterol Targets. Proceedings from satellite meeting 2004, British Cardiac Society Meeting.
16. Sacks FM, Alaupovic P, Moye LA et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000;102(16): 1886-92.
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.